Revenue Breakdown
Composition ()
No data
Revenue Streams
Boston Scientific Corp (BSX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Electrophysiology, accounting for 16.6% of total sales, equivalent to $840.00M. Other significant revenue streams include Endoscopy and Interventional Cardiology Therapies. Understanding this composition is critical for investors evaluating how BSX navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Boston Scientific Corp maintains a gross margin of 65.38%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.50%, while the net margin is 12.67%. These profitability ratios, combined with a Return on Equity (ROE) of 12.60%, provide a clear picture of how effectively BSX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BSX competes directly with industry leaders such as MDT and SYK. With a market capitalization of $113.10B, it holds a significant position in the sector. When comparing efficiency, BSX's gross margin of 65.38% stands against MDT's 59.93% and SYK's 62.61%. Such benchmarking helps identify whether Boston Scientific Corp is trading at a premium or discount relative to its financial performance.
